Treatment of Spontaneous Intracerebral Hemorrhage in Patients on Heparin Anticoagulation

When spontaneous intracerebral hemorrhage occurs in a patient receiving heparin-based anticoagulation, immediate intervention is required. The active anticoagulant effect must be addressed urgently, as it directly influences survival.

This protocol applies to patients with spontaneous intracerebral hemorrhage who are currently receiving unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH). The ongoing anticoagulant effect in this context is a critical management consideration.

Approach Overview

Management centres on stopping anticoagulation without delay and initiating reversal of the heparin effect as rapidly as possible. An intravenous agent is used to reverse the anticoagulant effect — fully in the case of UFH, and partially in the case of LMWH. The full reversal protocol, including agent selection and administration guidance, is available in the complete regimen.

Instant Access to Structured Evidence-Based Regimens

References

In patients with anticoagulant-associated spontaneous ICH, anticoagulation should be discontinued immediately and rapid reversal of anticoagulation should be performed as soon as possible after diagnosis of spontaneous ICH to improve survival.
In patients with unfractionated heparin (UFH)–associated spontaneous ICH, intravenous protamine is reasonable to reverse the anticoagulant effect of heparin.
In patients with low-molecular-weight heparin (LMWH)–associated spontaneous ICH, intravenous protamine may be considered to partially reverse the anticoagulant effect of heparin.
Intravenous protamine should not exceed 50 mg/10 min because of the risk of hypotension and bronchoconstriction; repeated smaller doses are preferable.

DOI: 10.1161/STR.0000000000000407

View source ↗